Charles River Laboratories (CRL)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-14
$272.88-0.08%
Close 2026-09-15 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-14
Research Workspace
Put CRL beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is contracting — down about 1% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 19%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 34% in its worst 12-month stretch.
View RiskCRL's growth in vaccine development and strong recent earnings performance support its valuation. Revenue grew 1% year over year in Q1 FY2026 and beat expectations by 126%. It trades at 28× P/E versus a peer median of 33×, indicating modest growth expectations priced in. The risk lies in management's delay on commitments, with a 21% probability of a miss next quarter. Peer multiples imply a price roughly in line with where it trades. This read is provisional.
Trailing returns as of 2026-09-15. CRL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 16 analysts currently covering CRL (as of Sep 2026).
Based on 10 Wall Street analysts offering 12-month price targets for CRL in the last 4 months.
Continue this research
Compare CRL with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CRL Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put CRL next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Enhance client experience and scientific portfolio
Growth inflection aligns with enhancing client experience.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
Current $272.88
The last 12 months of price, then the range of analyst 12-month targets from today’s $272.88.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Enhance client experience and scientific portfolio
Enhances scientific portfolio and client experience through vaccine work.
Advances: Enhance client experience and scientific portfolio
Enhances scientific portfolio and client experience through vaccine development.
Advances: Selective and strategic acquisitions
Upgrade indicates confidence in growth strategy.
Advances: Complete divestitures to refine portfolio
Raising EPS outlook supports divestiture strategy.
Advances: Complete divestitures to refine portfolio
Raising EPS outlook supports growth despite GAAP losses.
Advances: Selective and strategic acquisitions
Price target increase reflects M&A strategy success.
Advances: Enhance client experience and scientific portfolio
Sales exceeding estimates enhances client experience.